Improving MDS Outcomes From Diagnosis to Treatment: A Multidisciplinary Approach
There are many complexities associated with myelodysplastic syndromes (MDS) that a multispecialty team must address as a clinical-care unit. These complexities include obtaining adequate bone marrow specimens, identification and classification of MDS, the comorbidity rate of MDS patients, and the decision-making process for treatment. To address educational gaps associated with these complexities, ASH, the American Society for Clinical Pathology (ASCP), and the France Foundation designed comprehensive MDS-directed educational summits in 2017, which featured live events designed by world-class subject matter experts.
Participants actively engaged in multidisciplinary, interactive small-group activities, including case-based tumor board discussions and four break-out sessions on:
- Assessing low- or high-grade MDS
- Acquiring of morphologic mimics
- Applying the prognostic scoring system to cytogenetics
- Identifying the new role of molecular testing
The target audience for this program included hematologists, medical oncologists, hematopathologists, pathologists' assistants, hematology and oncology nurse practitioners, physician assistants, and medical laboratory scientists.
back to top